First day of trading in Arcede Pharma

Today is the first day of trading in Arcede Pharma. The company's main focus is on developing a new type of inhaled treatment for chronic obstructive pulmonary disease (COPD) and severe asthma. 

Arcede develops candidates for effective new drugs for chronic obstructive pulmonary disease (COPD) and severe asthma. The company's business concept is to develop drug candidates based on patent-pending compounds that have shown favorable results in preclinical studies compared to what is currently considered standard treatment. Arcede's lead candidate is designated RCD405, which is currently in development primarily for the treatment of COPD. The company's vision is to contribute to the alleviation of human suffering resulting primarily from respiratory diseases.

“The primary goal for Arcede Pharma is to develop new and innovative inhalation treatments with focus on chronic obstructive pulmonary disease (COPD) and severe asthma. COPD and severe asthma are important disease areas, especially since the global mortality is high and continuously increases. Existing treatments primarily have effect on the symptoms but not on the underlying disease. Many of the current therapies also show diminished effect over time and are in some cases related to safety issues. Thus, there is a huge unmet need for new treatments with an alternative mode of action.  Our drug candidate, RCD405, has demonstrated new and unique pharmacological properties within this disease area. A great potential for this drug candidate with its combination of anti-inflammatory and airway relaxing properties, as shown in several studies, is thus foreseen,” comments Mia Lundblad, CEO.

“Today we welcome Arcede Pharma to Spotlight. Arcede is a spin-off from Respiratorius that is listed on Spotlight. We are particularly pleased that Arcede has chosen to remain on Spotlight Stock Market and look forward to following their journey," says Carl-Henrik Nordberg, Head of Listing, Spotlight.

Press contact
Anders Kumlin, CEO of Spotlight
+46 79 006 65 66, ak@spotlightstockmarket.com

ABOUT SPOTLIGHT
Spotlight is the marketplace where investors and growth companies meet. At Spotlight, it is easier and safer for companies to be listed. We offer an overall solution that increases the visibility of our companies through unique media collaborations. Investors get through Spotlight the opportunity to become shareholders in approximately 160 growth companies from different businesses and countries, among those are Freetrailer, Bahnhof, and Synthetic MR.
spotlightstockmarket.com